In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deep-Pocketed Big Pharma Meets Spec Pharma's Challenge

Executive Summary

In early 2006, we noted in this space that in-licensing on the part of specialty pharmaceutical start-ups was rising relative to Big Pharma's in-licensing rate, with specialty pharmas even out-competing Big Pharma in some specific cases for rights to promising clinical programs. Since then, however, Big Pharma's unprecedented late-stage spending spree has far outpaced spec pharma's licensing, particularly in clinical stage deals.

You may also be interested in...



Specialty Pharma: Eating Big Pharma's Lunch, Not Just its Leftovers?

While not yet rivals to Big Pharma when it comes to clinical-stage licensing, spec pharmas have in some individual cases proven to be more favored partners than their Big Pharma competitors.

Intendis: Mid-Sized Specialist Spawns Small Specialist

In dermatology offshoot Intendis, Schering AG has created the ideal European crossbreed: a group with the management experience associated with spin-outs, and a revenue-generating side more typical of specialty pharma. The snag: Schering's retaining full ownership--for now.

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel